Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Primate cell – per se
Patent
1996-12-09
1999-08-10
Railey, II, Johnny F.
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Primate cell, per se
435325, 536 245, 514 44, C12N 510, C12N 1518, A61K 4800
Patent
active
059358564
ABSTRACT:
A method of inhibiting the growth of bFGF-dependent neoplastic cells is disclosed. The method includes the steps of accessing a selected colony of such cells and adding a bFGF-specific antisense primer to such colony. By performing the adding step, there is downregulating of the expression of colony-intracellular bound bFGF, and by performing the downregulating step, there is inhibiting of bFGF-promoted growth of cells in the colony.
REFERENCES:
patent: 5583116 (1996-12-01), Morrison
Zhang, Hinton, Surnock, Couldwell, Malignant glioma sensitivity to radiotherapy, high-dose tamoxifen, and hypericin; corroborating climcal response in vitro: case report, Neurosurgery, Mar. 1996 38(3), pp. 587-590; discussion 590-1 (Abstract only).
Schadendorf, Worm, Algermissen, Kohlmus, Czarnetzki, "Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity, "Cancer, Jan. 1, 1994 73(1), pp. 103-108 (Abstract only).
Miura, Terashima, Yamazaki, Ikeyama, Sasaki, Taki, Eukuda, Ishikawa, Yogita, Tashiro, "Secondary hepatic resections in a case of sigmoid colon cancer with multiple liver metastasis (H3) after successful continuous hepatic artery infusion chemotherapy oriented by in vitro chemosensitivity Jun. 1997 24(8), pp. 1031-1034 (Abstract only).
Krasagakis, Almond-Roesler, Zouboulis, Tebbe, Wartenberg, Wolff, Orfanos, "Merkel cell carcinoma: report of ten cases with emphasis on clinical course, treatment, and in vitro drug sensitivity, "Journal of the American Academy of Dermatology, May 1997, 36(5 Pt 1), pp. 727-732 (Abstract only).
Sevin, B., Perras, J., "Tumor heterogeneity and in vitro chemosensitivity testing in ovarian cancer," Am. J. of Obstetrics and Gynecology, Apr. 1997 176(4), pp. 759-766, discussion 766-8 (Abstract only). (1997).
Antisense 97: A roundtable on the state of the industry. Nature Biotechnology 15, 519-524.
Alama, A., Barbieri, F. B. Cagnoli, M. and Schettini, G. (1997), Antisense oligonucleotides as therapeutic agents. Pharmacological Research 36, 171-178.
Bennett, C., Condon, T., Grimm, S., Chan, H. & Chiang, M. (1994), Inhibition of endothelial cell-leukocyte adhesion molecule expression with antisense oligonucleotides, Journal of Immunology 152, 3530-3540.
Geary, R.S., Leeds, J.M., Scott, P.H., Monteith, D.K. and Levin, A.A. (1997). Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorthioate oligodeoxynucleotides. Anti-cancer Drug Design 12, 383-393.
Kondo, Y., Kondo, S., Tanaka, Y., Haqqi, T., Barna, B. and Cowell, J. (1998), Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis. Ontogene 16, 2243-2248.
Pienat, F. (1996), Animal models of antisense oligonucleotides: lessons for use in humans. Molecular Medicine Today 250-257.
Temsamani, J. and Guinot, P. (1997). Antisense oligonucleotides: a new therapeutic approach. Biotecnol. Appl. Biochem. 26, 65-71.
Yacyshyn, B. R., Bowen-Yacyshyn, M.B., Jewell, L. Tami, J.A., Bennett, C.F. Kisner, D.L. and Shanahan, W.R. (1998). A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 114, 1133-1142.
Becker et al., "Proliferation of human malignant melanomas is inhibited by antisense of oligonucleotides targeted against basic fibroblast growth factor," The EMBO Journal, vol. 8, No. 12, pp. 3685-3691, 1989.
Takahashi et al., "Inhibition of cell growth and tumorigenesis of human glioblastoma cells by a neutralizing antibody against human basic fibroblast growth factor," FEBS, vol. 288, No. 1, 2, pp. 65-71, 1991.
Lee et al., "Purification and Complementary DNA Cloning of a Receptor for Basic Fibroblast Growth Factor," Science, 245, pp. 57-60, Jul. 1989.
Abraham et al., "Human basic fibroblast growth factor: nucleotide sequence and genomic organization," The EMBO Journal, vol. 5, No. 10, pp. 2523-2528, 1986.
Sommer et al., "An Amino-Terminally Extended and Post-Translationally Modified Form of a 25kD Basic Fibroblast Growth Factor," Biochemical and Biophysical Research Communications, vol. 160, No. 3, pp. 1267-1274, 1989.
Branch, TIBS 23:45-50 (1998).
"Antisense '97: A roundtable on the state of the industry," Nature Biotechnology 15:519-528 (1997).
Melton, "Injected anti-sense RNAs specifically block messenger RNA translation in vivo," Proc. Natl. Acad. Sci. USA, vol. 82, pp. 144-148, Jan. 1985.
Ch'ng et al., "Antisense RNA complementary to 3' coding and noncoding sequences of creatine kinase is a potent inhibitor of translation in vivo," Proc. Natl. Acad. Sci. USA, vol. 86, pp. 10006-10010, Dec. 1989.
Takahashi et al., "Gene expression of fibroblast growth factors in human gliomas and meningiomas: Demonstration of cellular source of basic fibroblast growth factor mRNA and peptide in tumor tissues," Proc. Natl. Acad. Sci. USA, vol. 87, pp. 5710-5714, Aug. 1990.
Hori et al., "Suppression of Solid Tumor Growth by Immunoneutralizing Monoclonal Antibody against Human Basic Fibroblast Growth Factor," Cancer Research 51, pp. 6180-6184, Nov. 15, 1991.
Takahashi et al., "Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas," J. Neurosurg., vol. 76, pp. 792-798, May 1992.
Paulus et al., "Localization of basic fibroblast growth factor, a mitogen and angiogenic factor, in human brain tumors," Acta Neuropathologica, 79, pp. 418-423, 1990.
Zagzag et al., "Immunohistochemical Localization of Basic Fibroblast Growth Factor in Astrocytomas," Cancer Research 50, pp. 7393-7398, Nov. 15, 1990.
Stefanik et al., "Acidic and Basic Fibroblast Growth Factors are Present in Glioblastoma Multiforme," Cancer Research 51, pp. 5760-5765, Oct. 15, 1991.
Maxwell et al., "Expression of Angiogenic Growth Factor Genes in Primary Human Astrocytomas May Contribute to Their Growth and Progression," Cancer Research 51, pp. 1345-1351, Feb. 15, 1991.
Akutsu et al., "Localization of Acidic and Basic Fibroblast Growth Factor mRNA in Human Brain Tumors," Jpn. J. Cancer Res., 82, pp. 1022-1027, Sep. 1991.
Saxena et al., "Increased expression of genes from growth factor signaling pathways in glioblastoma cell lines," Oncogene, pp. 243-247, 1992.
Takahashi et al., "Gene Expression of Fibroblast Growth Factor Receptors in the Tissues of Human Gliomas and Meningiomas," Biochemical and Biophysical Research Communications, vol. 177, No. 1, pp. 1-7, 1991.
Rojanasakul, Advanced Drug Delivery Reviews 18:115-131 (1996).
Plenat, Molecular Medicine Today 2:250-257 (1996).
Palestine, Journal of the International Association of Physicians in AIDS Care 2(5):25-28 (1996).
Weiss, Science News 139:108-109 (1991).
Wickstrom, TIBTECH 10:281-287 (1992).
Legacy Good Samaritan Hospital And Medical Center
Railey II Johnny F.
LandOfFree
Method of inhibiting the growth of BFGF-dependent neoplastic cel does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of inhibiting the growth of BFGF-dependent neoplastic cel, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of inhibiting the growth of BFGF-dependent neoplastic cel will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1119640